CD33 and acute myeloid leukemia: Despite substantial toxicities, the ADC gentuzumab ozogamicin (GO) - a CD33 antibody conjugated to the potent enediyne DNA-binding cytotoxic antibiotic calicheamicin - is approved by the Food and Drug Administration for treating certain subtypes of AML.